A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

To join this study, you need to be an adult with type 2 diabetes, diagnosed within the last four years. Your diabetes should be moderately controlled, meaning your HbA1c (a measure of your average blood sugar over 2-3 months) needs to be between 7% and 9.5%. You should also have been taking only metformin, a common diabetes medicine, for at least three months, at a stable dose.

There are certain reasons why you might not be able to join. For example, if you have type 1 diabetes, or a history of certain serious conditions like chronic pancreatitis, some advanced eye conditions related to diabetes, or a high risk of heart problems like a recent heart attack or stroke. Also, if you have a family history of specific thyroid cancers, or if your kidneys aren't working well enough, you wouldn't be able to take part.

If you've recently taken medicines to help with weight loss, or have previously used certain injectable diabetes medicines called GLP-1 receptor agonists or insulin, you also wouldn't be eligible. The main idea is to study tirzepatide in people who are relatively new to diabetes treatment and don't have other complex health issues that might affect the study results.

If you decide to take part in this study, you would be given either tirzepatide or an intensified version of your usual diabetes treatment. You would have regular visits to the clinic for check-ups, blood tests, and other assessments to monitor your health and how the treatment is working. These visits might happen quite often at the beginning and then become less frequent as the study progresses. The total duration of the study would be explained to you in detail by the study team. You would also receive support and guidance from the research team throughout your participation.